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Previous work has demonstrated that bleomycin can directly stimulate alveolar macro-
phage secretion of fibroblast growth factors and monocyte chemotactic factors. In this
study, rat alveolar macrophages obtained by bronchoalveolar Iavage were examined for
the presence of bleomycin binding sites, which might mediate this response. The results
indicated that alveolar macrophages have specific, saturable, and reversible binding
sites. Both high- and low-affinity binding sites were found; each macrophage possessed
6.7 x io high-affinity sites, with a K of 528 nM, and 2.2 x 106 low-affinity sites, with a Kd
of 65 tM. The Kd of the high-affinity sites corresponds closely to the ED obtained from
dose-response curves of the bleomycin-stimulated secretion of both fibroblast growth
and monocyte chemotactic factors, suggesting that bleomycin stimulation of alveolar
macrophage function responses may be mediated by bleomycin interaction with these
sites.
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INTRODUCTION
Pulmonary fibrosis induced by the administration of
bleomycin in a number of rodent species has been
established as an animal model of the human disease
[1 1]. Alveolar macrophages isolated from animals with
bleomycin-induced fibrosis secrete cytokines [6, 15], fi-
broblast growth [2,4,8, 1 1] and inhibitory factors [3], and
leukocyte chemotactic factors [5,7], all of which are
thought to play important roles in mediating the fibrotic
reaction ofthe lungs to this drug. It has also recently been
demonstrated that similar results can be obtained by the
in vitro stimulation with bleomycin of alveolar macro-
phages from normal animals [4-6, 15].
The experiments presented here were undertaken to
determine if alveolar macrophages possess specific bind-
ing sites for bleomycin. Bleomycin internalization by
both tumor and normal cells has been established directly
by studies of drug uptake [9, 13] and indirectly by the
demonstration of chromosomal damage following the
incubation of cells with this drug [ 1 , 12 , 17] . However,
evidence that this internalization is a receptor-mediated
event has been lacking. In support of this hypothesis, it
has been demonstrated that the lethal effects of bleomy-
cm on Chinese hamster ovary (CHO) cells can be ablated
by pretreatment of cells with trypsin, implying the
presence of an intermediary membrane protein(s) in-
volved in the interaction of this drug and CHO cells [1].
As described here, the finding of bleomycin binding sites
on alveolar macrophages not only suggests a mechanism
by which these cells may be stimulated to secrete
monokines in bleomycin-induced pulmonary fibrosis but
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may also indicate a mode of action of this drug that is in
addition to its well known cytotoxic effects, mediated by
DNA strand breakage [ 1 , 1 1 , 12, 17].
MATERIALS AND METHODS
Materials
Bleomycin (Blenoxane) was a gift from Bristol Lab-
oratories (Bristol-Myers Company , Evansville, IN).
[S-methyl-3H]-bleomycin A.,, copper form (63-74 Ci!
mmol), was purchased from New England Nuclear
(Boston, MA) . High-pressure liguid chromatography
(HPLC)-grade CH3CN and CF1COH were obtained from
Pierce (Rockford, IL). Trypan blue and Wright’s stain
solution were from Sigma Chemical Co. (St. Louis,
MO). All other chemicals used to prepare buffers were of
reagent grade or better and were purchased from Fisher
Scientific Co. (Livonia, MI).
Methods
Purification of bleomycin A2. Blenoxane is a mix-
ture of bleomycin A, and B2 [15]; for use in binding
assays, bleomycin A2 was purified using reverse-phase
HPLC with a Waters Associates 5 10 chromatograph
system (Waters, Div. of Millipore, Milford, MA). The
column was an RP 318 (Biorad, Richmond, CA), with 3
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im particle size and measuring 4.6 X 250 mm. Elution
was accomplished isocratically at 22#{176}Cwith 89% solvent
A (0. 1% CF1CO2H in H2O) was 1 1 % solvent B (0.1%
CF1CO2H in CH1CN) and a flow rate of 1 .0 mi/mm.
Under these conditions, as detected by absorbance at 214
nm, bleomycin A2 and B2 eluted at 20 and 31 mm,
respectively. Material eluting at 20 mm from ten column
runs was collected using a fraction collector and pooled,
dried using vacuum centrifugation (Speed Vac, Savant
Instruments Inc. , Hicksville, NY), and resuspended in
95% ethanol, and stored at - 20#{176}C.Using this chroma-
tography method, the purity of each commercially pur-
chased batch of [3H]bleomycin A2 was also checked
before use and was found to consist of 97% bleomy-
cm A2.
Alveolar macrophage isolation. Macrophages were
obtained from male-specific pathogen-free Fisher 344
rats weighing 150-200 g (Charles River, Portage, MI)
exactly as reported previously [4]. Briefly, rats were
killed with an overdose of ketamine, and lungs were
perfused with 50 ml of sterile phosphate-buffered saline
(PBS) containing I mM EDTA and 0. 1% glucose to
remove blood. Lungs were then lavaged with ten, 10 ml
washes of this sterile PBS solution. Following isolation,
macrophages were resuspended in Hank’s balanced salt
solution (HBSS) supplemented with 1 mM CaCl2, 1 mM
MgSO4, and 0. 1% (wt!v) glucose, pH 7.2, and placed in
an ice water bath. These cells were 98% macrophages
by analysis of cytocentrifuge (Shandon Instruments,
Pittsburgh, PA) preparations stained with Wright’s stain.
Viability in all cases was >95% as assessed by exclusion
of trypan blue.
Bleomycin Binding Assays
Both radioactive and unlabeled bleomycin A2 were
dried using vacuum centrifugation to remove ethanol in
stock solutions, then resuspended in supplemented
HBSS. Polypropylene microfuge tubes (Sarstedt,
Princeton, NJ) were siliconized with Prosil-28 (PCR
Inc., Gainesville, FL) 24 hr prior to use. Cells, buffers,
and bleomycin were chilled to 4#{176}Cbefore use, and all
incubations with ligand were done at 4#{176}C.Each tube
contained 1 x 106 macrophages and the indicated con-
centration of [3H]bleomycin. Nonspecific binding was
determined as dpm bound in the presence of a 100-fold
concentration of unlabeled bleomycin A2. For kinetic
studies, incubations were at 4#{176}Cfor the times indicated;
for all other experiments, the incubations were for 60
mm. All incubations were stopped by rapid filtration and
washing of cells with ice-cold HBSS using a Brandel cell
harvester (Gaithersburg, MD). To reduce nonspecific
binding of the radiolabeled ligand, GF/B filters used in
harvesting cells were presoaked in 1% (wt!v) powdered
milk (Carnation) in HBSS just prior to use. All tubes
were washed eight times with 1.5 ml of ice-cold HBSS.
Filters were dried and placed into scintillation vials and
counted for radioactivity after the addition of scintillant
(Ready Protein; Beckmann Instruments, Fullerton, CA).
Analysis of radioactivity bound to macrophages.
Four million to six million macrophages er tube were
incubated with 169 nM (0.25 ig/ml) of [H]bleomycin
for 1 hour at 4#{176}Cas described above. Following the
incubation, tubes were centrifuged ( 1 ,500 rpm) for 5 mm
at 4#{176}C,and the supernatant was discarded. Cell pellets
were then resuspended in I ml ice-cold HBSS and
washed thrice by centrifugation; after the last wash, 50 pA
of 6.77 mM ( 10 mg/mi) nonradioactive bleomycin A2
was added followed by 500 pA of 5% trichloroacetic acid
(TCA) (4#{176}C)and vortexed. After 15 mm on ice, TCA-
precipitable protein was pelleted by centrifugation. The
resultant supernatants were filtered (0.2 pm Acro LC13
HPLC filters; Gelman Sciences, Ann Arbor, MI) prior to
analysis, using the HPLC method described above. Peak
absorbance of unlabeled bleomycin A2 added to the
samples was compared to the elution time of radioactivity
in the fractions. To ensure that [3H]bleomycin was
precipitated and unaltered by TCA, [3H] bleomycin was
incubated in the absence of macrophages then treated
with TCA as described for cell samples. Binding data
were analyzed using the LIGAND computer program
[10] to determine the number and affinity of the binding
sites.
RESULTS
When alveolar macrophages were incubated with
concentrations of 20-474 nM (0.3-0.7 pg/ml) of [3H]-
bleomycin , total binding increased with the concentration
of bleomycin present, saturating between 200 and 474
nM (Fig. 1). Nonspecific binding, in the presence of a
100-fold excess unlabeled bleomycin, increased linearly
with increasing concentrations of radioactive ligand. The
specific binding, represented as the total minus the
nonspecific radioactivity bound, increased in linear fash-
ion from 20 to 169 nM and did not increase further at
doses between 169 and 474 nM . Alveolar macrophages
thus appear to have specific and saturable membrane
binding sites for bleomycin A2.
To determine the kinetics of bleomycin binding to
these sites, macrohages were incubated with a saturating
concentration of [ Hibleomycin (338 nM) in the presence
or absence of 3.38 pM of unlabeled bleomycin for 2-60
mm. Binding of the ligand to macrophages was rapid,
approaching maximal levels after 10 mm (Fig. 2).
Although there was some increase in specifically bound
radioactivity from 10 to 80 mm, this difference was found
not to be statistically different in any of the three
experiments performed.
The reversibility of bleomycin binding to macrophages
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Fig. 1. Dose response of bleomycin binding. Macrophages
were incubated at 4#{176}Cfor 60 mm with the indicated concentra-
tion of [3H]bleomycin A2 in the presence (open circles) or
absence (triangles) of a 100-fold excess unlabeled bleomycin
A2. Specific binding (solid circles) was determined by subtract-
ing nonspecific binding from total binding. Data represent the
mean ± SE (of triplicate data points) of a representative exper-
iment from a total of 10 such experiments.
TIME (minutes)
Fig. 2. Kinetics of bleomycin binding. Macrophages were in-
cubated at 4#{176}Cfor the indicated times with 338 nM
(3H]bleomycin A2. Specific binding was determined as de-
scribed in the legend to Figure 1 . To examine reversibility, one
set of tubes was incubated for 60 mm with (3Hjbleomycin A2
prior to the addition of unlabeled bleomycin (arrow); specific
binding remaining at 2, 5, 10, and 20 mm after this addition was
then determined (broken line). Data represent the mean ± SE
(of triplicate data points) from a total of three such experiments.
[3H] bleomycin, then adding a 100-fold excess unlabeled
ligand for an additional time of 2-20 mm (Fig.2, broken
line). [3Hlbleomycin was rapidly displaced from binding
sites, with a reduction in specifically bound radioactivity
evident as early as 2 mm after addition of the unlabeled
drug; this displacement was essentially complete in 20
mm.
The characteristics of these binding sites were ana-
lyzed by the ability of increasing doses of cold ligand to
displace the binding of radioactive ligand. This was
Fig. 3. Scatchard plot of bleomycin binding. Macrophages
were incubated at 4#{176}Cfor 60 mm with the indicated total
concentration of bleomycin, a constant 271 nM of which was
H]bleomycin A2. Bound radioactivity was converted to
nmoles; data are the means of duplicate data points from four
experiments.
accomplished by incubating alveolar macrophages with a
constant concentration of 271 nM [3Hlbleomycin and
increasing concentrations of cold ligand. Analysis of the
data from four such experiments by LIGAND revealed
the presence of both high- and low-affinity binding sites
(Fig. 3). Each macrophage possessed an average of
6.7 x l0 sites, with an apparent Kd of 528 nM, and an
average of 2.2 x 106 low-affinity sites, with an apparent
Kd of 65 pM. Although low-affinity binding sites were
evident in all such experiments, it still remains a possi-
bility that these sites represented nonspecific binding to
the plasma membrane.
Finally, HPLC analysis of radioactive bleomycin
bound to macrophages under the binding assay conditions
described (60 mm, 4#{176}C)verified that [3Hlbleomycin A2
was not metabolized or degraded during the assay period
(Fig. 4A). Ninety percent of the radioactivity recovered
from macrophages incubated with [3H]bleomycin coin-
cided with peak absorbance of nonlabeled bleomycin A2.
In parallel controls of [3H]bleomycin incubated in the
absence of macrophages, 9 1% of the radioactivity recov-
ered eluted along with the unlabeled ligand (Fig. 4B).
DISCUSSION
The results of this study revealed that bleomycin could
bind to alveolar macrophages in a rapid, specific, and
saturable manner. Since all experiments were performed
at 4#{176}C,it is likely that cell-associated radioactivity
reflected bleomycin bound to membrane sites on the cell
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Fig. 4. HPLC analysis of radioactivity bound to macrophages.
[3Hjbleomycin was incubated with (A) or without (B) macro-
phages for 60 mm at 4#{176}C,after which cells were washed to
remove unbound ligand. Unlabeled bleomycin was added as a
tracer and to enhance dissociation of ligand from cells.
[3Hjbleomycin recovered in supernatants following TCA precip-
itation was isolated by HPLC as decribed in Methods. Radioac-
tivity (dpm) and absorbance were determined for each fraction.
Arrow indicates absorbance (214 nm) peak of unlabeled bleo-
mycin A2.
supported by the rapid reversibility of binding (Fig. 2)
and by studies with Ehlrich cells [9], which have shown
that the association ofthis drug with cells was irreversible
once it was internalized. Furthermore, studies on the
effects of temperature on the endocytosis of ligands by
alveolar macrophages [16] have indicated that internal-
ization is negligible at 4#{176}C.The findings presented here
are therefore compatible with the existence of bleomycin
binding sites on alveolar macrophages.
This demonstration of bleomycin binding sites on
macrophages is significant in that the Kd of the high-
affinity sites (528 nM) is within the concentration range
of the doses of bleomycin which evoke a biological
response. Previous work in this laboratory has shown that
alveolar macrophages obtained from normal rats incu-
bated with 6.77-670 nM bleomycin in vitro secreted both
monocyte chemotactic factor and macrophage-derived
growth factor (MDGF) [4,51. Jordana et al. [61 have
likewise demonstrated enhanced secretion of interleu-
kin-l by alveolar macrophages incubated with 339 nM
bleomycin. Time course experiments have also shown
that the kinetics of [3Hlbleomycin binding to macro-
phages (Fig. 2) are in accordance with the time course of
the secretion of both MDGF and monocyte chemotactic
factor, which were detectable as early as 30 mm follow-
ing stimulation with bleomycin in vitro [41 (also, unpub-
lished observations). The differences in the optimal
concentrations of bleomycin necessary for measuring
binding and that needed to elicit a biological response
may be due to the differences in the incubation temper-
atures used; binding assays were carried out at 4#{176}C
whereas experiments on the effects of bleomycin on the
secretion of MDGF and chemotactic activity [4,51 were
carried out at 37#{176}C.
Since bleomycin is a glycopeptide product of Strepto-
mvces verticullus [16], it is unclear why alveolar mac-
rophages would have specific binding sites for this drug.
Binding sites for such glycopeptides may serve in a
protective capacity similar to that suggested for the
receptors for bacterial peptides [14] and lipopolysaccha-
ride [ 18], allowing alveolar macrophages to respond to
airborne mold products. It also seems likely that the
bleomycin binding sites represent membrane sites with
other functions that can also bind to bleomycin; these
binding sites may be nonspecific, reacting with a range of
glycosalated compounds [ 161 , or specific receptors for
some endogenous mediator(s) capable of regulating mac-
rophage function in both homeostasis and disease [ 1 1].
The demonstration of these binding sites provides impor-
tant support for the existence of novel cellular and tissue
effects of this drug in addition to its well-known effects
on cytotoxicity and DNA strand scission [17].
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